ADMA Biologics, Inc. (NASDAQ:ADMA) Stock Position Raised by Prudential Financial Inc.

Prudential Financial Inc. lifted its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 1.1% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 524,430 shares of the biotechnology company’s stock after buying an additional 5,897 shares during the quarter. Prudential Financial Inc.’s holdings in ADMA Biologics were worth $8,994,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in ADMA. United Services Automobile Association acquired a new stake in ADMA Biologics in the 4th quarter worth approximately $255,000. Vanguard Group Inc. lifted its stake in shares of ADMA Biologics by 0.4% in the fourth quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company’s stock worth $312,109,000 after buying an additional 80,302 shares during the last quarter. Simplify Asset Management Inc. bought a new stake in shares of ADMA Biologics during the 4th quarter worth $6,606,000. Fox Run Management L.L.C. acquired a new position in ADMA Biologics in the 4th quarter valued at $328,000. Finally, KLP Kapitalforvaltning AS bought a new position in ADMA Biologics in the 4th quarter worth $794,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Stock Performance

NASDAQ ADMA opened at $20.26 on Friday. The firm has a market cap of $4.79 billion, a price-to-earnings ratio of 72.36 and a beta of 0.60. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 1-year low of $5.90 and a 1-year high of $23.64. The company has a 50 day moving average of $17.13 and a 200-day moving average of $18.15.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 price target on shares of ADMA Biologics in a research report on Tuesday, March 4th.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.